Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with atherosclerotic cardiovascular disease; however, many pati...
Guardado en:
Autores principales: | Chandni Bardolia, Nishita Shah Amin, Jacques Turgeon |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/66534c214f3c452c9cb96c64a988deac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
por: Rana K, et al.
Publicado: (2019) -
Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
por: Patrice Marques, et al.
Publicado: (2022) -
Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
por: Kosmas CE, et al.
Publicado: (2020) -
Characterization of novel stress degradation products of Bempedoic acid and Ezetimibe using UPLC–MS/MS: development and validation of stability-indicating UPLC method
por: Anuradha Vejendla, et al.
Publicado: (2021) -
Effect of Five Single Nucleotide Polymorphisms of ABCG5 and ABCG8 Genes on Ezetimibe Lipid-Lowering Response
por: Caamaño,José M, et al.
Publicado: (2012)